Athersys, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of novel regenerative medicine therapies designed to support the body’s natural healing processes. Central to its portfolio is MultiStem®, a patented allogeneic cell therapy derived from adult bone marrow–based multipotent progenitor cells. Athersys focuses on leveraging the anti-inflammatory, immunomodulatory and tissue-supportive properties of these cells to address serious conditions with significant unmet medical need, including acute respiratory distress syndrome (ARDS), ischemic stroke and inflammatory bowel disease.
The company’s research and development efforts are complemented by strategic collaborations aimed at advancing its lead product candidate through global clinical trials. In partnership with Healios K.K. in Japan, Athersys is sponsoring pivotal studies evaluating MultiStem in ischemic stroke, while additional trials are conducted in North America and Europe. These alliances enable streamlined regulatory pathways and broaden patient access across key markets, reflecting Athersys’s commitment to demonstrating safety, efficacy and scalability for its therapies.
Founded in 1995 and headquartered in Cleveland, Ohio, Athersys has built a multidisciplinary infrastructure encompassing discovery laboratories, process development facilities and clinical operations. Over its more than two decades of history, the company has advanced a deep scientific understanding of progenitor cell biology and established manufacturing processes designed to yield consistent, off-the-shelf therapeutic products. Athersys also maintains a network of academic and industry collaborators, contributing to a robust pipeline of cell and gene therapy initiatives beyond its core MultiStem platform.
Athersys is led by a seasoned management team and board of directors with extensive experience in biotechnology, pharmaceutical development and regenerative medicine. The executive leadership combines scientific expertise with regulatory and commercial acumen, guiding the company’s efforts from early-stage research through late-stage clinical development. Supported by a global network of scientific advisors and clinical investigators, Athersys continues to pursue innovative approaches to improve patient outcomes in areas of critical need.
AI Generated. May Contain Errors.
Free ATHX Stock Alerts